The key differences of SOC between the two anti-EGFR mAbs included the likelihood of “skin and subcutaneous tissue disorders”, “vascular disorders”, “respiratory, thoracic, and mediastinal disorders”, “cardiac disorders”, “hepatobiliary disorders”, “immune system disorders”, and “neoplasms benign, malignant, and unspecified (incl cysts and polyps)”. The gene discussed is EGFR; the disease is immune system disorder.